




















Long-Acting HIV Treatment Pipeline

	Preclinical	Phase I	Phase II/IIb	Phase III	Bridging	Approved
WEEKLY	 GS-5894		 ULO + ISL*  GS-1720 + GS-4182*	 ISL + LEN	 CAB + LEN*	 ABT
2-WEEKLY						 IBA
MONTHLY	 TLD	 GS-3107				
2-MONTHLY						 CAB + RPV
3-MONTHLY		 GS-3242				
4-MONTHLY		 CAB-ULA	 N6LS + CAB  3BNC117-LS + 10-1074-LS*			
6-MONTHLY	 DOR	 VH-079	 VH-499  VH-184  LTZ		 CAB + LEN*	 ARVs + LEN

ISL + LEN Update: Positive results from ISLEND-1 and ISLEND-2 were announced in June 2026; Gilead and Merck plan to file the data from the ISLEND trials with regulatory authorities globally.

Dosing Modality

-  Oral
-  Injectable
-  Implant
-  ARV infusion

-  Oral + injectable
-  Antibody infusion
-  Antibody infusion + injectable

Abbreviations

- ABT: Albuvirtide
- ARVs: Antiretrovirals
- BIC: Bictegravir
- CAB: Cabotegravir
- DOR: Doravirine
- IBA: Ibalizumab
- ISL: Islatravir
- LEN: Lenacapavir
- LTZ: Lenacapavir + teropavimab + znlirvimab
- RPV: Rilpivirine
- TLD: Tenofovir disoproxil fumarate + lamivudine + dolutegravir
- ULA: Ultra long-acting
- ULO: Ulonivirine

Notes

- *ULO + ISL: both phase II and phase II/III trials are ongoing
- *GS-1720 + GS-4182: phase II/III trial (WONDERS-1) is on hold; WONDERS-2 was terminated
- *3BNC117-LS + 10-1074-LS: time to viral rebound is measured at week 20
- *CAB + LEN: CAB is given every 2 months; LEN is given every 6 months